Fig. 7

Mfsd2a protein expression was decreased after TBI, and Mfsd2a deficiency resulted in a decreased concentration of S1P in the brain parenchyma. A, B Mfsd2a protein expression at different time points after TBI as measured by Western blotting. n = 4/group. C Immunofluorescence staining was performed with antibodies for Mfsd2a (green) and CD31 (red), and nuclei were stained with DAPI (blue). Scale bar = 10 μm. D, E Immunofluorescence staining revealed differential Mfsd2a protein expression (red) in brain ECs (green) (D). The corresponding statistics are shown in (E). n = 4/group. Scale bar = 50 μm. F, G WB analyses of the protein levels of Mfsd2a in brain tissues on day 3 after TBI. n = 4/group. H Concentrations of total S1P in the brain ECM on day 3 after TBI. n = 8/group. All data was analyzed by one-way ANOVA and Tukey’s multiple comparisons test, *P < 0.05 compared with the Sham group. All values are presented as the mean ± SD. (-): TBI only; (Ctr): control shRNA; (Vec): vehicle; (OE): Mfsd2a overexpression